Mounjaro vs Zepbound: Same Tirzepatide, Different Labels, Doses and Coverage

Mounjaro and Zepbound are the same medicine. Both contain tirzepatide, both are made by Eli Lilly, and both come in identical strengths from 2.5 mg to 15 mg injected once a week. The difference between Mounjaro and Zepbound is regulatory rather than chemical: Mounjaro is approved for type 2 diabetes while Zepbound is approved for weight management and obstructive sleep apnea, and that single distinction shapes who can be prescribed each brand, how the dose is chosen and whether insurance will pay.

When the FDA approved Zepbound in November 2023, its announcement noted that tirzepatide was already approved under the trade name Mounjaro. For a comparison with semaglutide, see our Zepbound vs Wegovy guide.

Is Mounjaro the same as Zepbound?

Mounjaro and Zepbound contain the same active ingredient at the same strengths and in the same injection formats. Both current labels list single dose pens, single dose vials, multi dose vials and single patient use KwikPens, and in both the multi dose vial and the KwikPen hold 4 doses each, so a 5 mg dose of Mounjaro and a 5 mg dose of Zepbound deliver the same molecule.

Tirzepatide activates two gut hormone receptors, GIP and GLP-1, which lowers blood sugar after meals, slows stomach emptying and reduces appetite in both brands alike. Our explainer on how tirzepatide's dual GIP and GLP-1 action works covers the mechanism. Both labels share the same boxed warning about thyroid C-cell tumors seen in rats, and because it is unknown whether tirzepatide causes these tumors in humans, both brands are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with a known serious hypersensitivity to tirzepatide.

What is the difference between Mounjaro and Zepbound?

The difference between Mounjaro and Zepbound is the FDA approved use printed on each label. Mounjaro is indicated, alongside diet and exercise, to improve blood sugar control in adults and in children 10 years of age and older with type 2 diabetes, and to reduce the risk of cardiovascular death, nonfatal heart attack or nonfatal stroke in adults with type 2 diabetes who are at high risk for these events.

Zepbound is indicated, together with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction long term in adults with obesity, or in adults with overweight who have at least one weight related condition. Zepbound is also indicated for moderate to severe obstructive sleep apnea in adults with obesity.

Can Mounjaro be prescribed for weight loss?

Mounjaro is not FDA approved for weight loss, although weight loss is a consistent effect in its diabetes trials. Prescribing Mounjaro to someone without type 2 diabetes for weight management would be off label, and because Zepbound exists for exactly that purpose, a prescriber who chooses tirzepatide for weight management would generally write for Zepbound.

In SURPASS-1, 478 adults with type 2 diabetes managed with diet and exercise alone were randomized to tirzepatide 5, 10 or 15 mg or placebo for 40 weeks. HbA1c, a measure of average blood sugar over recent months, fell from a baseline of 7.9% by 1.87%, 1.89% and 2.07% on the three doses, compared with a rise of 0.04% on placebo, and participants lost between 7.0 and 9.5 kg depending on dose.

Does Zepbound cause more weight loss than Mounjaro?

Zepbound does not cause more weight loss than Mounjaro at the same dose, because they are the same drug, and what changes the average result is the person taking it. Two Zepbound trials with matching 72 week designs show this.

In SURMOUNT-1, published in the New England Journal of Medicine in 2022, 2,539 adults with obesity or overweight and no diabetes lost an average of 15.0% of body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, compared with 3.1% on placebo. In SURMOUNT-2, published in The Lancet in 2023, 938 adults with type 2 diabetes lost an average of 12.8% on 10 mg and 14.7% on 15 mg, compared with 3.2% on placebo.

Because these are separate trials, the comparison is indirect, but across the two matched designs the participants with type 2 diabetes lost less weight on the same doses. A person with diabetes who moves from Mounjaro to Zepbound at the same dose should not expect a different response, since nothing about the medicine has changed.

How is the dose chosen on Mounjaro and on Zepbound?

Both brands start at 2.5 mg once weekly and rise in 2.5 mg steps after at least 4 weeks on each dose, but the goal of each step differs. On Mounjaro, the current label names 2.5 mg as the recommended starting dose and says to increase in 2.5 mg steps if additional glycemic control is needed, so the prescriber titrates toward a blood sugar goal rather than a fixed maintenance dose, with a maximum of 15 mg in adults and 10 mg in children 10 and older. On Zepbound, 2.5 mg is a starting dose only, and the label lists maintenance doses of 5 mg, 10 mg or 15 mg for weight management and 10 mg or 15 mg for sleep apnea, chosen by response and tolerability. Our tirzepatide dose escalation guide describes each step.

One practical difference follows from the populations. Both labels warn that combining tirzepatide with insulin or an insulin secretagogue such as a sulfonylurea may raise the risk of low blood sugar, including severe episodes, and that those doses may need to come down. The warning matters most for Mounjaro users, who are far more likely to take those drugs, whereas SURPASS-1, where participants took no other diabetes medicines, reported no clinically significant or severe hypoglycemia with tirzepatide.

What did the Mounjaro heart trial show?

SURPASS-CVOT found tirzepatide noninferior to dulaglutide, an older GLP-1 medicine with proven cardiovascular benefit, for preventing heart attack, stroke and cardiovascular death in people with type 2 diabetes and heart disease. The trial, published in the New England Journal of Medicine in 2025, randomized 13,299 patients to tirzepatide up to 15 mg or dulaglutide 1.5 mg weekly.

A major cardiovascular event occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group, a hazard ratio of 0.92. That met the test for noninferiority, but the superiority result was not statistically significant (P = 0.09), so the trial does not show tirzepatide is better than dulaglutide at preventing these events. Because SURPASS-CVOT enrolled only people with type 2 diabetes, the resulting indication sits on the Mounjaro label rather than Zepbound's.

Can teenagers take Mounjaro or Zepbound?

Mounjaro is approved for children and teens 10 years and older with type 2 diabetes, while Zepbound's label covers adults only. The pediatric approval rests on SURPASS-PEDS, published in The Lancet in 2025, which enrolled 99 participants aged 10 to under 18 whose diabetes was not controlled on metformin, basal insulin or both. After 30 weeks, HbA1c fell by an average of 2.23% in the combined tirzepatide groups and rose by 0.05% on placebo, and BMI fell by 7.4% on 5 mg and 11.2% on 10 mg. Tirzepatide is not approved for weight management in anyone under 18.

Why might insurance cover one brand and not the other?

Insurance coverage usually follows the FDA label, which is why the same molecule can be covered under one brand name and denied under the other. Many pharmacy plans cover diabetes medicines such as Mounjaro once type 2 diabetes is documented, while coverage of weight management medicines such as Zepbound varies widely by plan and employer, and a Mounjaro prescription for someone without type 2 diabetes is commonly rejected at prior authorization. Self pay prices change often, so current prices are best checked with the pharmacy or manufacturer.

Can someone switch from Mounjaro to Zepbound?

Switching between Mounjaro and Zepbound is possible because they are the same drug, usually because of a change in diagnosis or coverage, but the two should never be taken together. A switch is also a good moment to review other medicines, since insulin or sulfonylurea doses may need to fall as blood sugar improves, and the Mounjaro label advises people on oral contraceptives to switch to a contraceptive that is not taken by mouth, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.

Frequently asked questions